Alan Ezekowitz

CIK: 0001780209

Transaction Breakdown

Open Market Buys (P)4 (44.4%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (55.6%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

FULC

Fulcrum Therapeutics, Inc.

Director

OGN

Organon & Co.

Director

SEPN

Septerna, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (9 total)

FULC
Fulcrum Therapeutics, Inc.
Jun 30, 2026
Award(A)
Stock Option (right to buy)
Direct
32K shares-
OGN
Organon & Co.
Jun 12, 2026
Award(A)
Phantom Stock
Direct
17.9K shares at avg. $13.44-
FULC
Fulcrum Therapeutics, Inc.
Jun 26, 2025
Award(A)
Stock Option (right to buy)
Direct
36K shares-
SEPN
Septerna, Inc.
Jun 17, 2025
Award(A)
Stock Option (Right to Buy)
Direct
16.6K shares-
OGN
Organon & Co.
Jun 13, 2025
Award(A)
Phantom Stock
Direct
23.9K shares at avg. $10.04-
SEPN
Septerna, Inc.
Mar 7, 2025
Purchase(P)
Direct
13.3K shares at avg. $6.93$92K
SEPN
Septerna, Inc.
Mar 6, 2025
Purchase(P)
Direct
41.4K shares at avg. $6.00$248K
SEPN
Septerna, Inc.
Mar 5, 2025
Purchase(P)
Direct
37.8K shares at avg. $5.82$220K
SEPN
Septerna, Inc.
Mar 4, 2025
Purchase(P)
Direct
7.5K shares at avg. $6.35$48K

		Type	Shares	Price		Ownership
Jun 30, 2026	FULC Fulcrum Therapeutics, Inc.	Award(A) Stock Option (right to buy)	32,000	-	-	Direct
Jun 12, 2026	OGN Organon & Co.	Award(A) Phantom Stock	17,857	$13.44	-	Direct
Jun 26, 2025	FULC Fulcrum Therapeutics, Inc.	Award(A) Stock Option (right to buy)	36,000	-	-	Direct
Jun 17, 2025	SEPN Septerna, Inc.	Award(A) Stock Option (Right to Buy)	16,623	-	-	Direct
Jun 13, 2025	OGN Organon & Co.	Award(A) Phantom Stock	23,904	$10.04	-	Direct
Mar 7, 2025	SEPN Septerna, Inc.	Purchase(P)	13,319	$6.93	$92,270	Direct
Mar 6, 2025	SEPN Septerna, Inc.	Purchase(P)	41,355	$6.00	$248,130	Direct
Mar 5, 2025	SEPN Septerna, Inc.	Purchase(P)	37,835	$5.82	$220,260	Direct
Mar 4, 2025	SEPN Septerna, Inc.	Purchase(P)	7,491	$6.35	$47,544	Direct

1-9 of 9 transactions

About Ezekowitz Alan

Ezekowitz Alan (SEC CIK 0001780209) files insider reports with the SEC as Director of Fulcrum Therapeutics, Inc. (FULC), Director of Organon & Co. (OGN) and Director of Septerna, Inc. (SEPN).

Signal8 holds 8 ownership filings by Ezekowitz Alan (1 Form 3, 7 Form 4), filed between Oct 24, 2024 and Jul 2, 2026. Those filings report 9 transactions, from Mar 4, 2025 to Jun 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Ezekowitz Alan's filings is in CAMBRIDGE, MA.

Recent filings by Ezekowitz Alan

Jun 30, 2026: Grant or award of FULC derivative securities (Form 4, code A).
Jun 12, 2026: Grant or award of OGN derivative securities (Form 4, code A).
Jun 26, 2025: Grant or award of FULC derivative securities (Form 4, code A).
Jun 17, 2025: Grant or award of SEPN derivative securities (Form 4, code A).
Jun 13, 2025: Grant or award of OGN derivative securities (Form 4, code A).

Other insiders filing for Fulcrum Therapeutics, Inc. (FULC)

TANG KEVIN, 10% Owner
Banks Sonja, Director
Dorton Katina, Director
Gould Robert J, Director
Haviland Kate, Director
King Rachel K., Director

How to read Form 4 transaction codes